Balanced news tone
News Sentiment
7630 sentiment intelligence
IMPACT THERAP-B news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
3 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-3.1% over one week, -46.4% over four weeks, trend inactive, and below fair value.
Precision-drug maker Impact Therapeutics ignites IPO frenzy
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
-3.1%
Price reacting lower
Trend fit
Trend inactive
-46.4% over four weeks
Fair value
-42.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
0
Neutral
3
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
thebambooworks.com
Direct company coverage
Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- thebambooworks.com
BioWorld News
Direct company coverage
Metis Techbio, Impact Tx cleared for Hong Kong IPOs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- BioWorld News
TradingView
Direct company coverage
IMPACT Therapeutics, Inc. Class H Financial Statements – HKEX:7630
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:38
- Source
- TradingView